Kyverna Therapeutics Common Stock Net Income
| KYTX Stock | 9.76 0.75 7.14% |
As of the 25th of January, Kyverna Therapeutics secures the Downside Deviation of 8.16, risk adjusted performance of 0.0761, and Mean Deviation of 5.95. Kyverna Therapeutics Common technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.
Kyverna Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kyverna Therapeutics' valuation are provided below:We have found one hundred seventeen available fundamental ratios for Kyverna Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Kyverna Therapeutics last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -114.7 M | -109 M | |
| Net Loss | -114.7 M | -109 M | |
| Net Loss | (3.82) | (3.63) |
Kyverna | Net Income | Build AI portfolio with Kyverna Stock |
Latest Kyverna Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Kyverna Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Kyverna Therapeutics financial statement analysis. It represents the amount of money remaining after all of Kyverna Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Kyverna Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kyverna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (127.48 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Kyverna Net Income Regression Statistics
| Arithmetic Mean | (44,509,302) | |
| Coefficient Of Variation | (80.27) | |
| Mean Deviation | 27,473,874 | |
| Median | (26,350,000) | |
| Standard Deviation | 35,729,050 | |
| Sample Variance | 1276.6T | |
| Range | 101.1M | |
| R-Value | (0.72) | |
| Mean Square Error | 663.7T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | (5,065,715) | |
| Total Sum of Squares | 20425T |
Kyverna Net Income History
Other Fundumenentals of Kyverna Therapeutics
Kyverna Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Kyverna Therapeutics is extremely important. It helps to project a fair market value of Kyverna Stock properly, considering its historical fundamentals such as Net Income. Since Kyverna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kyverna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kyverna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kyverna Therapeutics. If investors know Kyverna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kyverna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kyverna Therapeutics is measured differently than its book value, which is the value of Kyverna that is recorded on the company's balance sheet. Investors also form their own opinion of Kyverna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kyverna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kyverna Therapeutics' market value can be influenced by many factors that don't directly affect Kyverna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kyverna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kyverna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kyverna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kyverna Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kyverna Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kyverna Therapeutics.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Kyverna Therapeutics on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Kyverna Therapeutics Common or generate 0.0% return on investment in Kyverna Therapeutics over 90 days. Kyverna Therapeutics is related to or competes with Allogene Therapeutics, Lexeo Therapeutics, Cabaletta Bio, Contineum Therapeutics, Editas Medicine, Mereo BioPharma, and Atea Pharmaceuticals. Kyverna Therapeutics is entity of United States More
Kyverna Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kyverna Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kyverna Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 8.16 | |||
| Information Ratio | 0.0816 | |||
| Maximum Drawdown | 55.75 | |||
| Value At Risk | (9.60) | |||
| Potential Upside | 10.86 |
Kyverna Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kyverna Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kyverna Therapeutics' standard deviation. In reality, there are many statistical measures that can use Kyverna Therapeutics historical prices to predict the future Kyverna Therapeutics' volatility.| Risk Adjusted Performance | 0.0761 | |||
| Jensen Alpha | 0.6016 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.0796 | |||
| Treynor Ratio | 0.421 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kyverna Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Kyverna Therapeutics January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0761 | |||
| Market Risk Adjusted Performance | 0.431 | |||
| Mean Deviation | 5.95 | |||
| Semi Deviation | 7.85 | |||
| Downside Deviation | 8.16 | |||
| Coefficient Of Variation | 1093.22 | |||
| Standard Deviation | 7.96 | |||
| Variance | 63.38 | |||
| Information Ratio | 0.0816 | |||
| Jensen Alpha | 0.6016 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.0796 | |||
| Treynor Ratio | 0.421 | |||
| Maximum Drawdown | 55.75 | |||
| Value At Risk | (9.60) | |||
| Potential Upside | 10.86 | |||
| Downside Variance | 66.57 | |||
| Semi Variance | 61.67 | |||
| Expected Short fall | (6.50) | |||
| Skewness | (0.71) | |||
| Kurtosis | 4.05 |
Kyverna Therapeutics Backtested Returns
Kyverna Therapeutics appears to be slightly risky, given 3 months investment horizon. Kyverna Therapeutics has Sharpe Ratio of 0.0869, which conveys that the firm had a 0.0869 % return per unit of risk over the last 3 months. By analyzing Kyverna Therapeutics' technical indicators, you can evaluate if the expected return of 0.68% is justified by implied risk. Please exercise Kyverna Therapeutics' Risk Adjusted Performance of 0.0761, downside deviation of 8.16, and Mean Deviation of 5.95 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Kyverna Therapeutics holds a performance score of 6. The company secures a Beta (Market Risk) of 1.71, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kyverna Therapeutics will likely underperform. Please check Kyverna Therapeutics' value at risk, kurtosis, market facilitation index, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Kyverna Therapeutics' current price movements will revert.
Auto-correlation | 0.17 |
Very weak predictability
Kyverna Therapeutics Common has very weak predictability. Overlapping area represents the amount of predictability between Kyverna Therapeutics time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kyverna Therapeutics price movement. The serial correlation of 0.17 indicates that over 17.0% of current Kyverna Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.17 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.84 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Kyverna Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Kyverna Therapeutics Common reported net income of (127.48 Million). This is 137.35% lower than that of the Biotechnology sector and 281.99% lower than that of the Health Care industry. The net income for all United States stocks is 122.33% higher than that of the company.
Kyverna Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kyverna Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kyverna Therapeutics could also be used in its relative valuation, which is a method of valuing Kyverna Therapeutics by comparing valuation metrics of similar companies.Kyverna Therapeutics is currently under evaluation in net income category among its peers.
Kyverna Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kyverna Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kyverna Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Kyverna Fundamentals
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 415.65 M | ||||
| Shares Outstanding | 59.61 M | ||||
| Shares Owned By Insiders | 9.10 % | ||||
| Shares Owned By Institutions | 54.12 % | ||||
| Number Of Shares Shorted | 3.55 M | ||||
| Price To Book | 3.83 X | ||||
| Gross Profit | (137.19 M) | ||||
| EBITDA | (125.2 M) | ||||
| Net Income | (127.48 M) | ||||
| Total Debt | 8.24 M | ||||
| Book Value Per Share | 3.47 X | ||||
| Cash Flow From Operations | (114.25 M) | ||||
| Short Ratio | 1.33 X | ||||
| Earnings Per Share | (3.73) X | ||||
| Target Price | 29.6 | ||||
| Number Of Employees | 129 | ||||
| Market Capitalization | 581.76 M | ||||
| Total Asset | 304.64 M | ||||
| Retained Earnings | (263.52 M) | ||||
| Working Capital | 256.85 M | ||||
| Net Asset | 304.64 M |
About Kyverna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kyverna Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kyverna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kyverna Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kyverna Stock Analysis
When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.